143PD: Bevacizumab and pemetrexed versus pemetrexed alone as maintenance therapy for patients with advanced nonsquamous NSCLC: Results of the expanded SAKK19/09 trial
ContributorsGautschi, Oliver; Li, Q; Matter-Walstra, K; Betticher, D; Frueh, M; Rauch, D; Pless, M; Froesch, P; Mach, Nicolas; Ochsenbein, A
Published inJournal of thoracic oncology, vol. 11, no. 4 Suppl, S120
Publication date2016
Affiliation
Citation (ISO format)
GAUTSCHI, Oliver et al. 143PD: Bevacizumab and pemetrexed versus pemetrexed alone as maintenance therapy for patients with advanced nonsquamous NSCLC: Results of the expanded SAKK19/09 trial. In: Journal of thoracic oncology, 2016, vol. 11, n° 4 Suppl, p. S120. doi: 10.1016/S1556-0864(16)30253-2
Main files (1)
Article (Published version)
Identifiers
- PID : unige:93755
- DOI : 10.1016/S1556-0864(16)30253-2
- PMID : 27198283
ISSN of the journal1556-0864
